Septerna Stock Plunges 64% After Halting Phase 1 Trial Of SEP-786

(RTTNews) - Septerna Inc. (SEPN) is down 63.58 percent during Tuesday's trading, shedding $8.34 to trade at $4.62 after announcing the discontinuation of its Phase 1 clinical trial for SEP-786, a treatment for hypoparathyroidism.

SEPN opened at $4.30 and has ranged between $4.72 and $4.85 throughout the day, with a volume of 4.47 million shares, significantly higher than the average of 312,806. The stock has now fallen to its 52-week low.

The decision follows the observation of two severe adverse events related to elevated bilirubin levels in healthy volunteers, though liver enzyme levels remained unaffected, and the bilirubin levels were reversible.